{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-136728","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.503557+00:00","generated_at":"2026-06-02T02:25:13.972580+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"UroGen Q1 net loss $32.3M; JELMYTO revenue up 10% to $18.8M; UGN-102 NDA on track","bullets":["Net loss $32.3M ($0.97/share) vs $30.2M ($1.30) in Q1 2023; JELMYTO revenue $18.8M, +10% YoY.","FY2024 guidance reiterated: JELMYTO revenue $95-102M; operating expenses $175-185M.","UGN-102 rolling NDA submission to complete Q3 2024; ENVISION 12-month DOR data event June 13.","IND accepted for UGN-103; Phase 3 in LG-IR-NMIBC planned for 2024.","Cash $164.5M; OLYMPUS post-hoc shows JELMYTO median duration of response 47.8 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-136728","json":"https://secwatch.observer/filing/0001193125-24-136728.json","markdown":"https://secwatch.observer/filing/0001193125-24-136728.md","text":"https://secwatch.observer/filing/0001193125-24-136728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524136728/0001193125-24-136728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524136728/d804276d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:25:13.972580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15fc25c21c825360774262c42c2061ba664bd594","claim":"UroGen Pharma Ltd. reported the first quarter ended March 31, 2024 results: revenue $18.8 million, net income net loss of $32.3 million or ($0.97) per basic and diluted share, EPS ($0.97) per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"• Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free periods more than 47.8 months in LG-UTUC • JELMYTO ® demonstrated continued growth with net product sales of $18.8 million in Q1, compared with $17.2 million in Q1 2023 representing ~10% YoY growth • IND accepted for UGN-103, next-generation novel mitomycin-based formulation of UGN-102 to treat","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524136728/0001193125-24-136728-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$18.8 million"},{"label":"Net income","value":"net loss of $32.3 million or ($0.97) per basic and diluted share"},{"label":"EPS","value":"($0.97) per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}